Proficio Capital Partners LLC Buys New Shares in Vericel Co. (NASDAQ:VCEL)

Proficio Capital Partners LLC bought a new stake in Vericel Co. (NASDAQ:VCEL) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 17,406 shares of the biotechnology company’s stock, valued at approximately $956,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. FMR LLC boosted its holdings in Vericel by 1.0% in the third quarter. FMR LLC now owns 2,372,812 shares of the biotechnology company’s stock valued at $100,251,000 after purchasing an additional 22,461 shares during the period. Congress Asset Management Co. lifted its holdings in Vericel by 12.6% during the 4th quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company’s stock worth $79,847,000 after buying an additional 162,419 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Vericel by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock worth $48,768,000 after buying an additional 9,613 shares during the last quarter. Geneva Capital Management LLC lifted its holdings in Vericel by 61.4% during the 3rd quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company’s stock worth $46,660,000 after buying an additional 420,078 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Vericel by 4.6% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,079,048 shares of the biotechnology company’s stock worth $45,590,000 after buying an additional 47,108 shares during the last quarter.

Vericel Stock Up 1.6 %

Shares of VCEL stock opened at $49.56 on Friday. The stock has a market capitalization of $2.48 billion, a PE ratio of 826.14 and a beta of 1.78. Vericel Co. has a 52-week low of $39.12 and a 52-week high of $63.00. The stock’s 50-day moving average price is $56.48 and its 200 day moving average price is $51.92.

Insider Activity at Vericel

In related news, insider Jonathan Siegal sold 3,908 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $61.99, for a total value of $242,256.92. Following the transaction, the insider now owns 1,206 shares in the company, valued at $74,759.94. The trade was a 76.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the transaction, the director now owns 26,595 shares in the company, valued at $1,662,187.50. This trade represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,500 shares of company stock worth $466,200 in the last quarter. Company insiders own 5.20% of the company’s stock.

Wall Street Analyst Weigh In

VCEL has been the subject of a number of recent analyst reports. Canaccord Genuity Group lifted their price target on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Vericel in a report on Friday, February 28th. Truist Financial reissued a “buy” rating and issued a $61.00 target price (down from $67.00) on shares of Vericel in a report on Monday, March 3rd. BTIG Research boosted their target price on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $62.29.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.